AU2007329480A1 - Indazole compounds - Google Patents

Indazole compounds Download PDF

Info

Publication number
AU2007329480A1
AU2007329480A1 AU2007329480A AU2007329480A AU2007329480A1 AU 2007329480 A1 AU2007329480 A1 AU 2007329480A1 AU 2007329480 A AU2007329480 A AU 2007329480A AU 2007329480 A AU2007329480 A AU 2007329480A AU 2007329480 A1 AU2007329480 A1 AU 2007329480A1
Authority
AU
Australia
Prior art keywords
independently
nrarb
compound
heteroaryl
deleted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007329480A
Other languages
English (en)
Inventor
Min-Liang Kuo
Chung-Ming Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Taiwan University NTU
National Yang Ming Chiao Tung University NYCU
Original Assignee
National Taiwan University NTU
National Yang Ming Chiao Tung University NYCU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Taiwan University NTU, National Yang Ming Chiao Tung University NYCU filed Critical National Taiwan University NTU
Publication of AU2007329480A1 publication Critical patent/AU2007329480A1/en
Assigned to National Chio Tung University, NATIONAL TAIWAN UNIVERSITY reassignment National Chio Tung University Request for Assignment Assignors: Kuo, Min- Liang, SUN, CHUNG-MING
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/561,2-Diazoles; Hydrogenated 1,2-diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007329480A 2006-12-05 2007-12-03 Indazole compounds Abandoned AU2007329480A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87304106P 2006-12-05 2006-12-05
US60/873,041 2006-12-05
PCT/US2007/086220 WO2008070599A1 (en) 2006-12-05 2007-12-03 Indazole compounds

Publications (1)

Publication Number Publication Date
AU2007329480A1 true AU2007329480A1 (en) 2008-06-12

Family

ID=39492604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007329480A Abandoned AU2007329480A1 (en) 2006-12-05 2007-12-03 Indazole compounds

Country Status (9)

Country Link
US (1) US7825261B2 (enExample)
EP (1) EP2091329A4 (enExample)
JP (1) JP2010511721A (enExample)
KR (1) KR20090127867A (enExample)
CN (1) CN101616587A (enExample)
AU (1) AU2007329480A1 (enExample)
CA (1) CA2671543A1 (enExample)
TW (1) TWI433672B (enExample)
WO (1) WO2008070599A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
ES2574253T3 (es) 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CA2913085A1 (en) 2013-05-23 2014-11-27 Bernhard Lindenthal Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101713303B1 (ko) 2015-12-24 2017-03-07 강원대학교산학협력단 2h-인다졸 유도체의 제조방법
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021067393A1 (en) * 2019-10-01 2021-04-08 Memorial Sloan Kettering Cancer Center SMALL MOLECULE INHIBITORS OF Id PROTEINS
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
CA2356638A1 (en) * 1998-12-23 2000-07-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
MXPA05010824A (es) * 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
BRPI0409888A (pt) * 2003-04-18 2006-05-23 Memory Pharm Corp derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ4阻害剤としてのピラゾール誘導体
ATE519488T1 (de) * 2004-12-27 2011-08-15 Novartis Ag Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤

Also Published As

Publication number Publication date
KR20090127867A (ko) 2009-12-14
JP2010511721A (ja) 2010-04-15
US20080132501A1 (en) 2008-06-05
US7825261B2 (en) 2010-11-02
WO2008070599A1 (en) 2008-06-12
CN101616587A (zh) 2009-12-30
EP2091329A1 (en) 2009-08-26
CA2671543A1 (en) 2008-06-12
TWI433672B (zh) 2014-04-11
EP2091329A4 (en) 2011-02-23
TW200836720A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
US7825261B2 (en) Indazole compounds
CN101619043B (zh) 喹唑啉衍生物及其医药用途
JP4394442B2 (ja) 抗炎症剤として有用なスピロ−ヒダントイン化合物
EP1389617B1 (en) Heterocyclic compound and antitumor agent containing the same as active ingredient
KR101311757B1 (ko) 2-아미노-7,8-디히드로-6h-피리도[4,3-d]피리미딘-5-온
US20040209902A1 (en) Aminoquinoline compounds
CN100402523C (zh) 杂环化合物及以其为有效成分的抗肿瘤药
CA2295625C (en) Imidazole derivatives as mdr modulators
PT2125776T (pt) Compostos espiro substituídos como inibidores da angiogénese
US5376666A (en) Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
CZ281937B6 (cs) Substituované bifenylpyridony
KR20080006614A (ko) 증식 질환의 치료에 유용한 hsp90 억제제인2-아미노-퀴나졸린-5-온
AU2005227954B2 (en) Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
JP2009504664A (ja) Kspインヒビターとしての置換イミダゾール化合物
JP5667934B2 (ja) 新規2環性複素環化合物からなる医薬
KR101373911B1 (ko) Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한화합물 및 방법
JP4828142B2 (ja) 新規な融合ピラゾリル化合物
US5409926A (en) AT-2 antagonist inhibition of vascular restenosis
CN101287734A (zh) 2-氨基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮
US8383662B2 (en) Bicyclic heteroaryl compounds
CN112094223A (zh) 一类脲基四氢咔唑类小分子有机化合物及用途
JP2005187449A (ja) 4,4−ジフルオロ−1,2,3,4−テトラヒドロ−5h−1−ベンゾアゼピン誘導体又はその塩
JPH04235983A (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
HK1118823B (en) 2-amino-7,8-dihydro-6h-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NATIONAL TAIWAN UNIVERSITY; NATIONAL CHIO TUNG UNI

Free format text: FORMER APPLICANT(S): SUN, CHUNG-MING; KUO, MIN- LIANG

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application